Get started
Author

Brian J. Chernak

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes
2018 · Abdullah Mahmood Ali, Yumin Huang, et al. · Blood Advances · 26
Cells deficient for Krüppel-like factor 4 exhibit mitochondrial dysfunction and impaired mitophagy
2019 · William M. Rosencrans, Zachary H. Walsh, et al. · European Journal of Cell Biology · 18
Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies
2021 · Brian J. Chernak, Raajit K. Rampal · International review of cytology · 10
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies
2025 · Ioanna Mosialou, Abdullah M. Ali, et al. · Cancer Cell · 7
Molecular Deconvolution of Bone Marrow Adipose Tissue Interactions with Malignant Hematopoiesis: Potential for New Therapy Development
2024 · Drenka Trivanović, Marko Vujačić, et al. · Current Osteoporosis Reports · 6
Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
2020 · Brian J. Chernak, Filiz Sen, et al. · HemaSphere · 4
Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
2023 · Brian Chernak, Marta Galan-Diez, et al. · Blood · 2
PDF
Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy
2026 · Brian J. Chernak, Raajit Rampal · Leukemia & lymphoma/Leukemia and lymphoma · 1
Genetic predictors of clonal contraction and hematologic response in IDH mutant myeloid malignancies
2026 · Amy Song, Yi Chen, et al. · medRxiv
PDF
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
2026 · Aaron T. Gerds, Jason Gotlib, et al. · Journal of the National Comprehensive Cancer Network
Abstract CT191: The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of a Phase I study
2026 · Jan Bewersdorf, Andriy Derkach, et al. · Cancer Research
A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.
2025 · Chi-Joan How, Gabriela Hobbs, et al. · Blood
The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study
2025 · Jan Philipp Bewersdorf, Andriy Derkach, et al. · Blood
PDF
Abstract 3783: Niche driven inflammatory regulation in the pathogenesis and treatment of myeloid malignancies
2025 · Pallavi Budgude, Brian Chernak, et al. · Cancer Research
Abstract 3076: A niche driven mechanism determines response to ATRA and a mutation-independent therapeutic approach forMDS and AML
2025 · Ioanna Mosialou, Abdullah M. Ali, et al. · Cancer Research
Mutant RUNX1, SETBP1 and IDH Mutant Allele Dynamics As Biomarkers of Hematologic Response to IDH Inhibitors in Myeloid Malignancies
2024 · Brian Chernak, Amy Song, et al. · Blood
PDF
External validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes.
2023 · Brian Chernak, Abdullah Ali, et al. · Journal of Clinical Oncology
PDF
Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients
2020 · Brian J. Chernak, Emily Coskun, et al. · Blood
Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients
2017 · Abdullah Mahmood Ali, Yu-Min Huang, et al. · Blood
Works count: 19
Citation count: 74
H-index: 5
I10-index: 3
Year
Topic
Type